M2-polarized TAMs can secret CCL15 to bind C-C motif chemokine receptor 1 (CCR1) on tumor cells and activate the NF-κB pathway, thereby inducing gefitinib resistance.216 Metformin, an inhibitor of CCL15 expression, maintains gefitinib sensitivity. This evidence concerns the gene CCL15 and neoplasm.